The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Micaela Laber, MPH, MBA
Advertisement
Articles by Micaela Laber, MPH, MBA
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
February 8th 2023
Advertisement
Advertisement
Trending on AJMC
1
Special Report: The Oncology Care Model, 10 Years Later
2
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
3
Long-Term Extension Data Support Durable Benefit of Rilzabrutinib in Persistent, Chronic ITP: David Kuter, MD, DPhil
4
Contributor: Turning Headwinds Into Momentum—How Value-Based Care Can Help Payers Manage Costs and Regain Stability
5